

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271

WWW.FULBRIGHT.COM

August 28, 2002

STEVEN L. HIGHLANDER PARTNER SHIGHLANDER@FULBRIGHT.COM

DIREC DIAL TELEPHONE FACSIMILE:

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Comprissioner for Patents, Washington, DC 20231, or the date below:

August 28, 2002

Date

tever L. Highlander

Commissioner for Patents Washington, DC 20231

Re:

U.S. Patent Application No. 10/044,842 entitled "NOVEL ANTISEPTIC

DERIVATIVES WITH BROAD SPECTRUM ANTIMICROBIAL ACTIVITY FOR THE

IMPREGNATION OF SURFACES" by Issam Raad et al.

Our Reference: UTSC:669US Client Reference: MDA00-052

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A19, C1-C12).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:669US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L Highlander

Reg. No. 37,642

SLH/cmb Encl.: as noted

25200018.1

Group Art Unit: 1810/CENTER 52002 IN THE UNITED STATES PATENT AND TRADEMARK OFF plication of:

Serial No.: 10/044,842

ssam Raad et al.

Filed: January 11, 2002

For: NOVEL ANTISEPTIC DERIVATIVES

WITH BROAD SPECTRUM

ANTIMICROBIAL ACTIVITY FOR THE **IMPREGNATION OF SURFACES** 

Atty. Dkt. No.: UTSC:669US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:

August 28, 2002

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/UTSC:669US.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

August 28, 2002

Form PTO-1449 (modified)

Land Publications for Applicant's

NFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket N . UTSC:669US

Serial No. 10/044,840 Chilips Too.

Applicant

Issam Raad, et al.

Filing Date: January 11, 2002

U.S. Patent Documents See Page 1

**Foreign Patent Documents** See Page 1

See Page 2

## **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
•	A1	4,107,121	8/15/78	Stoy	260	29.6	11/20/75
-	A2	4,442,133	4/10/84	Greco et al.	427	2	2/22/82
	A3	4,895,566	1/23/90	Lee	604	266	6/15/88
	A4	4,917,686	4/17/90	Bayston et al.	604	265	11/23/87
	A5	4,952,419	8/28/90	De Leon et al.	427	2	3/12/89
	A6	5,013,306	5/7/91	Solomon et al.	604	265	3/21/90
	A7	5,362,754	11/8/94	Raad et al.	514	566	11/12/92
	A8	5,616,119	4/1/97	Davis	604	19	6/2/95
	A9	5,624,704	4/29/97	Darouiche et al.	427	2.24	4/24/95
	A10	5,709,672	1/20/98	Illner	604	265	11/1/95
	A11	5,756,145	5/26/98	Darouiche	427	2.24	11/8/95
	A12	5,820,607	10/13/98	Tcholakiran et al.	604	265	6/5/95
	A13	5,820,918	10/13/98	Ronan et al.	427	2.1	7/11/96
-	A14	5,853,745	12/29/98	Darouiche	424	423	3/26/97
	A15	5,902,283	5/11/99	Darouiche et al.	604	265	3/26/97
=	A16	6,162,487	12/19/00	Darouiche	427	2.14	3/27/97
	A17	6,165,484	12/26/00	Raad et al.	424	405	8/25/98
1	A18	6,193,994 B1	2/27/01	Lee et al.	424	444	3/4/99
	A19	6,267,979 B1	7/31/01	Raad et al.	424	405	8/25/98

## **Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

25128034.1

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

See Page 2

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

See Page 1

Exam. Init.	Ref. Des.	Citation
	C1	Bhatnager and Sundaram, "Studies on antibacterial properties of gentian violet impregnated silastic," <i>Indian J. Med. Res.</i> , [A]97:206-208, 1993.
	C2	Gonzalez et al., "Risk factors for fungemia in children infected with human immunodeficiency virus: a case control study," Clin. Infect. Dis., 23:515-521, 1996.
	C3	Lecciones et al., "Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes," Clin. Infect. Dis., 14:875-883, 1992.
	C4	Platt and Bucknall, "MIC tests are not suitable for assessing antiseptic handwashes," J. Hosp. Infect., 11:396-397, 1988.
	C5	Raad and Bodey, "Infectious complications of indwelling vascular catheters," <i>Clin. Infect. Dis.</i> 15:197-210, 1992.
	C6	Raad et al., "Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial," Ann. Intern. Med., 127(4):267-274, 1997.
	C7	Raad, "Intravascular-catheter-related infections," Lancet, 351:893-898, 1998.
	C8	Solomon and Sherertz, "Antibiotic releasing polymers," Controlled Release, 6:343-352, 1987.
	C9	Tacconelli et al., "Central venous catheter-related sepsis in a cohort of 366 hospitalized patients," Eur. J. Clin. Microbiol. Infect. Dis., 16:203-209,1997.
	C10	Tumbarello et al., "Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay," J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol., 19:490-497, 1998.
	C11	Van Delden and Iglewski, "Cell-to-cell signaling and Pseudomonas aeruginosa infections," Emerging Infectious Disease, 4(4):551-560, 1998.
	C12	Wey et al., "Risk factors for hospital-acquired candidemia," Arch. Intern. Med. 149:2349-2353 1989.

25128034.1

See Page 1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.